Painful bladder syndrome/interstitial cystitis (PBS/IC) is a chronic disease of unknown etiology characterized by vague bladder pain and nonspecific urinary symptoms, such as urgency and frequency. Although it was initially considered to be a rare condition, its prevalence has significantly increased, possibly because of different definitions used and greater physician awareness. Because of the multiple diagnostic criteria used, there is significant variation in its prevalence. In addition, there is often a delay in the diagnosis of PBS/IC. It affects predominantly women of middle age, and it significantly decreases quality of life. Diagnosis of PBS/IC is mainly a diagnosis of exclusion; there are no characteristic symptoms or pathognomonic findings. Therefore, it is important to rule out diseases that have a similar clinical picture (i.e., urinary infections, bladder carcinoma) but definite therapies and worse prognosis if left untreated. PBS/IC management suffers from lack of evidence; many therapies are empiric or based on small studies and case series. Treatment includes supportive therapies (psychosocial, behavioral, physical), oral treatments, and intravesical treatments, whereas other more invasive treatments such as electric neuromodulation and reconstructive surgery are reserved for refractory cases. Physicians should always keep in mind the diagnosis of PBS/IC in patients presenting with chronic urinary symptoms after excluding other more common diseases.
A lthough painful bladder syndrome/interstitial cystitis (PBS/IC) was first described in 1887 by Skene and despite numerous conferences of professionals involved in PBS/IC diagnosis, efforts to establish a universally accepted definition have been futile (1) . Nevertheless, its prevalence is increasing, possibly because of greater physician awareness of PBS/IC or because of different definitions or diagnostic criteria applied in recent studies.
Definition
The National Institute of Diabetes, Digestive and Diseases of the Kidney (NIDDK) suggested in 1988 the use of diagnostic criteria for enrollment in PBS/IC studies (2, 3) , including bladder pain or urinary urgency, glomerulations or Hunner's ulcers during cystoscopy or hydrodistention, and absence of other pathologies (Table 1 ). In addition, it described minimum criteria regarding age, duration of symptoms, degree of frequency, and nocturia. However, with the use of the NIDDK definition, up to 60% of patients clinically diagnosed to have PBS/IC by experienced clinicians were being missed (3) .
The International Continence Society (ICS) proposed in 2002 the term "painful bladder syndrome." It was defined as the complaint of "suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and nighttime frequency in the absence of proven infection or other obvious pathology" (4) . Several scientific meetings and organizations adopted the ICS definition with minor modifications (1) . In addition, the European Society for the Study of PBS/IC (ESSIC) decided later to rename PBS as bladder pain syndrome (BPS), proposing use of findings from cystoscopy and hydrodistention for patient staging (5) . Some authors suggest that PBS/IC represents at least two different entities, the classic and the nonulcer; the latter is associated with younger age at diagnosis and milder reduction in bladder capacity.
Epidemiology
The prevalence of PBS/IC varies because of the several definitions and methods used to estimate it. Whereas in older studies, PBS/IC seems to be relatively rare (6) (18.1/100,000 women and 10.6/100,000 men), recent studies report a higher prevalence of 52 to 197/100,000 women and 40 to 70/100,000 men (7, 8) when diagnosis is made by the physician. However, prevalence is much higher when diagnosis is based on selfreport of previous PBS/IC diagnosis (501-865/100,000 patients) (9) ; prevalence of PBS/IC symptoms is even higher when estimated by the use of questionnaire without clinical examination (10,11) (450 -11,200/100,000 patients). PBS/IC is more common in women, with a female/male ratio that ranges from 5:1 to 10:1 (12) . Median age at diagnosis is 42 to 46 yr old (13) , whereas men are diagnosed at a younger age (7) .
Pathophysiology
Although PBS/IC underlying pathophysiology is incompletely understood, it involves primarily urothelial permeability changes, along with mast cell activation and neurogenic inflammation (14) (Figure 1 ). In PBS/IC, damage of the protective bladder lining leads to impaired urothelial cell barrier function. Consequently, urinary solutes penetrate the epithe-lium and activate sensory nerve endings, leading to pain and inflammation (15) . Consistent with this theory, bladder epithelial cells in PBS/IC patients are shown to produce anti-proliferative factor (APF) (16) , which may further contribute to the impaired urothelial cell barrier. In addition, urothelial cells from PBS/IC patients fail to release prostaglandin E 2 , which is crucial for the protection and repair of the urothelium (17) . Other bladder epithelial abnormalities reported in PBS/IC include abnormal cellular architecture on electron microscopy (18) and abnormal uroplakin expression assessed by reversetranscriptase PCR (19) . Mast cell may play a central role in PBS/IC pathophysiology: patients not only have increased number of mast cells but also Ͼ70% of them are activated versus 10% in healthy controls (20) . Moreover, substances that are indicative of mast cell activation such as IL-6, histamine, and tryptase are increased in the urine of PBS/IC patients (17) . Interestingly, Tamm-Horsfall protein concentration in the urine of PBS/IC patients may not differ from controls, but it is qualitatively different containing less sialic acid (21) ; this altered protein may thus be involved in PBS/IC pathogenesis.
Neurogenic upregulation may also play a role in the pathogenesis of PBS/IC. The purinergic pathway has been shown to be upregulated in urothelial cells from PBS/IC patients (22) , with the neural upregulation occurring both peripherally and centrally (23) . However, it is undetermined whether the neurogenic inflammation that characterizes PBS/IC is the cause or the result of other previous unknown events.
PBS/IC could result from different environmental triggers in a genetically susceptible individual (24 -26) ; this approach may explain its increased prevalence among first-degree relatives and monozygotic twins pairs. In this respect, PBS/IC could be considered a spectrum of clinical phenomena in a genetically susceptible individual, where an environmental trigger (such as trauma or infection) provides the "second hit," leading to an uncontrolled inflammatory response.
Clinical Presentation
Clinical picture can be variable (27) . PBS/IC often has insidious onset and remains undiagnosed for years, because not all of the initial symptoms appear simultaneously but rather present gradually. Symptoms include pain (considered as essential diagnostic criterion by all classification schemes), nocturia, urinary frequency, and urgency. Early in the disease, symptoms may be mild and intermittent, but they tend to become constant and severe over time (27) . Frequency is a common clinical presentation, followed by urgency and pain. Pain can initially present as discomfort, burning, or pressure sensation that evolves to severe pain. It is usually localized to the suprapubic area; however, it is often reported in the lower abdomen, urethra, vaginal area, scrotum, and rectum. PBS/IC patients tend to void frequently to relieve pain (28) ; in contrast, voiding to avoid urine leakage is typical in overactive bladder syndrome (OAB), where urgency is the main symptom. Although absence of nocturia was initially considered inconsistent with PBS/IC diagnosis, it is now known that it can appear later in the progress of the disease (2) .
PBS/IC may present with flares lasting for several days and remissions. Beverages containing biogenic amines, caffeine, smoking, stress, allergies, and sexual activity are considered precipitating factors (20, 29) . In addition, women report exacerbation of symptoms during the premenstrual week (29) . Pain is associated with sexual activity, leading to severe sexual dysfunction and poor quality of life (30) ; dyspareunia is a common finding in PBS/IC patients. In addition, women with PBS/IC have significantly more hysterectomies and other pelvic surgeries in comparison with age-matched controls (31); most of them are done before PBS/IC diagnosis. However, it is unclear whether these operations were performed because of pelvic pain related to undiagnosed PBS/IC or the surgery itself contributed to chronic pelvic pain.
Several systemic and autoimmune conditions are more frequent in PBS/IC patients than the general population (32): irritable bowel syndrome and systemic lupus erythematosus are many folds more frequent in PBS/IC patients. In addition, the increased prevalence of Sjö gren disease, rheumatoid arthritis, and the presence of autoantibodies in PBS/IC patients provide a possible background for an autoimmune underlying pathophysiologic mechanism (33) . Therefore, PBS/IC is often considered a manifestation of a systemic disorder rather than a specific organ disorder (34) . The correlation of PBS/IC with other unexplained physical symptoms and certain psychiatric conditions (35) along with the absence of pathognomonic findings may further support this theory.
Diagnosis
Because there are no definitive diagnostic tests, PBS/IC remains a diagnosis of exclusion; the diagnostic steps aim to rule out other diseases and overlapping syndromes. Awake cystometric capacity Ͼ350 ml using a fill rate of 30-100 ml/min, Absence of intense urge to void at 100 ml gas or 150 ml liquid,
History and Physical Examination
A thorough history and physical examination is particularly significant. Medical history should include history of symptoms (pain, nocturia, frequency, urgency), urinary infections, pelvic surgeries, central nervous system, or autoimmune diseases. Symptoms of PBS/IC typically worsen during the premenstrual week in contrast with endometriosis (36) . In addition, because PBS/IC occurs in flares, it is often misdiagnosed as recurrent urinary tract infection (UTI) or prostatitis, with the resolution incorrectly attributed to antibiotic therapy and not to the disease's natural pattern (37) . There are no specific physical findings in PBS/IC patients. However, a careful pelvic examination is essential to rule out vaginitis, vulvar lesions, urethral diverticula, and pelvic floor dysfunction, whereas it may show anterior vaginal wall and bladder base tenderness in women with PBS/IC.
The O'Leary Sant symptom and problem index along with the pelvic pain and urgency/frequency symptom scale are the most commonly used surveys, which were developed for monitoring progress after treatment, but both have been used as screening tools as well (38 -40) . A voiding diary can be extremely helpful for documenting voiding volume and frequency, not only for screening reasons but also for monitoring response to treatment.
Laboratory Tests
There are no laboratory (urine or blood) tests that will identify PBS/IC. It is crucial, however, to rule out overlapping diseases. Urinalysis and urine culture are essential to exclude UTI. In presence of hematuria, and particularly in older patients with a history of smoking or with other risk factors for bladder malignancy, urine cytology is significant. Cystoscopy may be essential in severe cases of hematuria. In the quest for noninvasive techniques for PBS/IC diagnosis, many urinary biomarkers were tested: urinary histamine, tryptase, and others were found to be elevated in a subgroup of PBS/IC patients but they were not prospectively studied as a diagnostic tool. In addition, urine IL-6 levels were increased only in newly diagnosed patients (20) , and whether it could be used as a diagnostic marker or as a predictor to response to treatment is still controversial (41) . Recently, anti-proliferative factor (APF) was suggested as a candidate biomarker for PBS/IC diagnosis (42) because it was shown to have increased activity in the bladders of PBS/IC patients in comparison with asymptomatic controls. Using proteomic techniques and quantitative biomarker analysis, Canter et al. (43) reported that PBS/IC patients had decreased concentration of uromodulin, kininogen, and increased levels of inter-␣-trypsin inhibitory heavy chain H4 in their urine; these substances could be used as biomarkers, but further studies are needed. Nitric oxide (NO), which is considered a nonspecific marker of inflammation (44) , was tested in a recent study (45) as a possible diagnostic tool: NO levels in the bladder were shown to correlate with the degree of inflammation and with the response to treatment, but the limitation of this technique was that measurement of NO levels required catheterization.
Other Diagnostic Procedures
Potassium Sensitivity Test. In the potassium sensitivity test (PST), a potassium chloride solution and sterile water are instilled sequentially directly in the bladder; increased pain with the potassium solution is considered a positive test and indicates epithelial dysfunction. However, the PST has its limitations: patients with chronic UTIs, bladder outlet obstruction, or OAB may not respond to intravesical potassium (29) . In addition, the PST has 75% sensitivity and specificity and is not recommended for diagnostic purposes because of its low prognostic value (20) .
Urodynamic Studies. Urodynamic studies are optional, and their use remains rather controversial. Nevertheless, they can be helpful in excluding OAB and in evaluating bladder dysfunction, especially in male patients.
Cystoscopy. Whereas cystoscopy was initially considered mandatory for diagnosis (2, 3, 46) , it is now performed at the physician's discretion. In the United States, it is performed mainly when it is essential to rule out other pathology and particularly underlying malignancy; however, in Europe, it is considered to be important for diagnosis and for disease classification. In addition, it can be helpful in guiding treatment (e.g., patients with reduced bladder capacity are unlikely to benefit from oral pharmaceutical treatment). Hydrodistention of the bladder, which consists of filling the bladder (under general anesthesia) with normal saline or sterile water beyond its normal capacity, can also be performed during cystoscopy. With this technique, Hunner's ulcers (patches) and glomerulations (pin-point petechial hemorrhage) can be more easily visualized. Glomerulations, once considered diagnostic of PBS/ IC, can also be found in other bladder pathologies and in asymptomatic women (47). Hunner's ulcers or Hunner's lesions were originally described by Hunner (48) in 1915 and initially considered as pathognomonic for PBS/IC. They represent positive signs for PBS/IC and designate a specific type of the disease, not only cystoscopically, but also with reference to histology, response to therapy, and prognosis (49) . This type was later defined as classic PBS/IC. Biopsy. There are no specific findings in biopsies of patients with PBS/IC (47); therefore, biopsy in not essential for diagnosis. However, it is indicated in a patient with suspected PBS/IC, when specific bladder pathologies such as carcinoma, dysplasia, or tuberculosis must be excluded. In addition, biopsy findings can be useful in identifying subgroup of patients who are most likely to benefit from specific treatments: patients with mastocytosis or excessive eosinophils in bladder biopsy may be more effectively treated with antihistamines (50).
Treatment
Because of the absence of definitive diagnostic tests and standard clinical criteria, PBS/IC is a diagnosis of exclusion; as a result, the design of randomized controlled trials (RCTs) for its management is extremely difficult. Therefore, data regarding the efficacy of therapies are limited and often based on uncontrolled studies or case series. Although Ͼ180 different treatments have been tried in PBS/IC, data are still inconclusive; only pentosan polysulfate sodium (PPS) was found to be modestly beneficial (51) . Three recent reviews focused on PBS/IC treatment (20, 51, 52) , whereas a recent well-designed RCT gave promising results for therapy with intravesical alkalized lidocaine (53) . Nevertheless, treatment of PBS/IC can be divided to supportive (nonspecific) management and to specific therapeutic modalities that target the suggested underlying pathophysiology.
Supportive Therapies
Supportive therapies include general measures that can alleviate symptoms or prevent exacerbations. Psychosocial support is significant because it is an essential part of any chronic pain treatment. Because depression is not uncommon in PBS/IC patients, referral to specialists is necessary if such a diagnosis is suspected. Other comorbid diseases that are common in PBS/IC patients (i.e., inflammatory bowel disease) should be diagnosed and treated aggressively. All factors associated with symptom exacerbation such as allergies, certain foods, and body position should be avoided.
Behavioral therapy can be effective in improving PBS/IC 
Specific Therapies
It remains an important goal to properly select patients with PBS/IC for treatments based on individual patient characteristics. Currently, the most common stratification is based on presence/absence of visible ulcers on cystoscopy. This is a useful distinction because visible ulcers can be fulgurated (56) . There are many indicators of bladder inflammation in PBS/IC (ulcers, NO, urine markers, bladder biopsy findings); however, it is unknown which of these are most predictive of treatment response (57) . Specific therapies include intravesical, oral treatments, and other treatments, with the latter being used predominantly in refractory cases. Table 2 includes the most common PBS/IC treatments for which there is at least one RCT. Other treatments for which there are no RCTs conducted are shown in Table 3 .
Oral Treatments
PPS is the only oral medication approved by the FDA for treatment of PBS/IC. The approved dose is 100 mg three times per day. Only trials for PPS-based therapy had enough numbers to allow pooled analysis of effect in a recent systematic review, where PPS was showed to be beneficial with a relative risk of 1.78 for patient-reported improvement in symptoms (95% confidence intervals, 1.34 to 2.35) (51). However, the welldesigned NIDDK-supported trial (Interstitial Cystitis Clinical Trial Group) failed to provide evidence for the efficacy of PPS treatment in PBS/IC, although the study might be underpowered (58) . In addition, increased doses of PPS (300 and 600 mg daily) have not been associated with greater efficacy but with more frequent adverse effects (59) . PPS treatment within 6 mo after PBS/IC diagnosis is associated with greater efficacy in comparison with late treatment (60) . However, administration for a prolonged period may be required before clinical response is noted, since oral treatment leads to low concentration in the bladder; it has been shown that only 6% of PPS is excreted in urine (61) . The most commonly reported side effects include nausea, diarrhea, headache, and alopecia (62) .
Although evidence is limited, hydroxyzine is considered by many urologists as a first-line treatment. Its anxiolytic and anti-cholinergic effect along with its ability to inhibit bladder inflammation may explain its efficacy (63) . Dose starts at 25 mg daily, given at bedtime, and should be slowly titrated to 50 to 75 mg. Prolonged administration (3 to 4 mo) may be needed before any beneficial effect is shown; 40% of patients receiving hydroxyzine for more than 3 mo reported improvement in an open label study (64) . However, the previously aforementioned NIDDK-supported trial in a accurately designed RCT failed to show the efficacy of hydroxyzine (58) .
Amitriptyline, the oral tricyclic anti-depressant, is commonly used in PBS/IC treatment. Mechanism of action includes regulation of pain through modulation of neuronal dysfunction. The only placebo-RCT available showed amitriptyline to be effective with significant improvement of symptoms (65) . However, there were no details regarding the use of active or inactive placebo. The median dose used was 75 mg/d (range, 15 to 150 mg/d). In addition, long-term follow-up (19.0 Ϯ 12.5 mo) of patients treated with amitriptyline was correlated with a 64% response rate (66) . It is noteworthy that there was a significant withdrawal of patients in this study because of nonresponse and anti-cholinergic side effects. Therefore, patients should start on the lowest possible dose (10 mg daily) and titrate up to the effective dose (66, 67) . Results (unpublished) presented by the Interstitial Cystitis Collaborative Research Network (IC-CRN) at the 2009 American Urological Association meeting showed lack of efficacy of amitriptyline. Cyclosporine is a calcineurin inhibitor that may act in PBS/IC through inhibition of activation of T cells or mast cell activation. Data are limited, but it gave promising results in small open-label studies (68, 69) and in a recent RCT, where patients treated with cyclosporine reported a higher treatment response in comparison with PPS treatment after 6 mo (70). In addition, the response correlated with a decrease in urinary epidermal growth factor concentration, whereas patients in the cyclosporine group had a tendency toward lower urinary IL-6 levels (71). However, symptoms may return after treatment cessation, and side effects are more common in the cyclosporine group.
Oral cimetidine was found to be very effective, with significant symptom improvement in the only RCT available (72). However, there was no apparent histologic change in the bladder mucosa after treatment, and the mechanism of symptom relief is rather undefined. l-Arginine is a substrate for NO synthase, and it was used in PBS/IC based on data that NO synthase activity is decreased in the urine of PBS/IC patients. Two recent RCTs reported limited efficacy with no or marginal improvement in the treatment group (Table 2) (73, 74) . Although some patients reported that use of antibiotics might decrease their symptoms, a recent RCT failed to show benefit from oral administration of antibiotics for 18 wk (75) .
There are numerous other oral treatments, which have been used in PBS/IC, particularly in refractory cases, but data are scarce and based on small open label studies, sometimes of ambiguous design (Table 3) ; RCTs are urgently needed. Steroids were used in PBS/IC based on the hypothesis that ulcers signify underlying bladder inflammation (57, 76) ; nevertheless, there is the caveat that normal bladders are rarely biopsied, so there are no well-established cut-points at which bladder inflammation is defined as abnormal. Data that steroids are effective in classic PBS/IC are extremely limited, and further well-designed studies are needed before steroid use can be widely recommended. Soucy and Gregoire (77) reported symptom improvement after corticosteroid use in 14 patients with refractory PBS/IC who failed conservative treatment.
Montelukast, a leukotriene receptor antagonist, which is used in asthma treatment, was also reported to reduce symptoms in 10 patients with detrusor mastocytosis (78) . Nonsteroidal antiinflammatory drugs have been used in a small open label study with 37 patients who reported symptom improvement (79); however, the anti-depressant agent doxepin was given simultaneously making difficult the evaluation of efficacy of each medication and in addition, symptoms recurred after the discontinuation of the treatment. Methotrexate was used in a study of 9 patients with refractory PBS/IC, with improvement in one half of them in pain control but not urinary frequency (80) . The significant side effects of these medications should always be considered.
Intravesical Therapies
Intravesical treatments for PBS/IC were recently analyzed in a Cochrane review (52) : only bacillus Calmette-Guerin (BCG) and oxybutin seemed to be relatively well tolerated and gave the most promising results. However, it was repeatedly noted by the authors that the available evidence is extremely limited.
Dimethyl sulfoxide (DMSO) is the only intravesical medication approved by the FDA. The mechanism of action includes inhibition of mast cell activation with analgesic and inflammatory effects. Two rather small RCTs support its beneficial effect (81, 82) . However, the side effects of DMSO (garlic-like smell, taste) makes it almost impossible to perform a real placebocontrolled RCT. In addition, in these two early studies, DMSO was administered every 2 wk, whereas nowadays in common practice, DMSO is administered once weekly. Finally, in the crossover study by Peeker et al. (82) , where DMSO could follow BCG treatment and vice versa, there was no clear washout period between treatments, making it difficult to determine which treatment was actually beneficial.
Intravesical administration of BCG was initially shown to be beneficial in PBS/IC through an unknown immunologic mechanism; however, an RCT in 248 PBS/IC patients showed that BCG treatment was only slightly superior to placebo (83) . In addition, in two other RCTs, the group receiving intravesical BCG had no or marginal improvement (82, 84) . Oxybutynin, which has an anti-cholinergic effect reducing bladder spasm, was shown to significantly increase bladder capacity and was correlated with reduced frequency and improved quality of life (85) . In this RCT, 36 patients in both groups with PBS/IC had significant improvement favoring the oxybutynin group.
Because PBS/IC is associated with chronic pain produced by sensitized local bladder afferent nerves, a rational approach would be to install local anesthetic. Toward this direction, intravesical lidocaine have been used for many years but offered only superficial bladder anesthesia, because lidocaine cannot be converted to a lipid-soluble base form in the acidic bladder environment. However, when combined with bicarbonate, its absorption increases, giving promising results (86) . A recent well-designed RCT showed that intravesical alkalinized lidocaine is effective in a large proportion of PBS/IC patients not only for short-term relief, but it may also contribute to long-term downregulation of bladder sensory nerves (53) . In addition, duration of treatment may enhance the clinical benefits without significant adverse effects or rebound effects such those associated with narcotics' administration.
PPS has also been used intravesically based on the hypothesis that it replenishes the protective bladder lining composed primarily by glycosaminoglycans layer; additionally, only 6% of PPS is excreted in urine when given orally (61) . A recent RCT showed that combined therapy of intravesical and oral PPS led to two-fold reduction in the severity of PBS/IC symptoms compared with oral therapy alone (87) .
Despite initial promising results, the effectiveness of resinifera toxin and botulinum toxin type A (88) in the treatment of PBS/IC remains unknown. We recently showed that the results from available clinical trials including three RCTs (Table 2) regarding the efficacy of resinifera toxin are rather inconclusive (89) . Consistent with this, the aforementioned Cochrane review found no evidence of effect of resinifera toxin for most outcomes; in addition, it reduced patient compliance by causing pain (52) .
Several other intravesical treatments have been tried in PBS/IC patients, but data are limited, coming from small uncontrolled open-label studies. Heparin has been widely used intravesically for PBS/IC in combination with lidocaine and bicarbonate (86) as a substitute for bladder layer or as a inhibitor of inflammation (20) . However, when used as monotherapy, it was not shown to provide any relief. Hydrodistention is mainly used for diagnosis, and it remains rather controversial whether it can also offer short-term relief (55) ; there is only a small open-label study that showed that adjuvant hydrodistention under epidural anesthesia can be effective in almost 70% of patients (90) . Similarly, the use of intravesical hyaluronic acid in PBS/IC may be effective as shown in several open-label studies (91) (92) (93) (94) (95) (96) , but in a recent review, we concluded that it cannot be recommended because of the limited available data (97) . A new open-label study, however, supports that the administration of intravesical hyaluronic acid plus chondroitin sulfate may represent a safe and efficacious method of treatment in PBS/IC (98) ( Table 3) .
Other Treatments
In cases of PBS/IC, which are refractory to oral and intravesical treatment, therapeutic options include transurethral resection of ulcers, reconstructive surgery, and neuromodulation. The cost-benefit ratio should always be considered before one of these invasive treatments is recommended.
Transurethral resection of ulcers in PBS/IC patients led to satisfactory response in 90% of patients with classic PBS/IC (99); the mechanism might involve the removal of the intramural nerve endings. However, this study was not randomized, and patients underwent hydrodistention before transurethral resection of ulcers. In addition, the patients of the study (classic PBS/IC) belong to a subgroup of PBS/IC patients that represent only 5% of PBS/IC patients.
Based on the hypothesis that PBS/IC symptoms may arise from a chronic simulation and pathologic upregulation of the pelvic nerves, sacral neuromodulation using an implantable neuroprosthetic device (which was shown to be effective in treating urgency and frequency) was reported to decrease narcotic requirements in refractory PBS/IC (100). Although results are rather promising, drawbacks of this technique include high cost, pain at the neurostimulator site, need for surgical revisions, and risk of infection. Because of the less invasive technique used and the technical improvements of the newer devices, complications rate of this technique is expected to decrease (101) .
Reconstructive surgery for PBS/IC patients gave disappointing results in the past (102) . In addition, a recent study (103) showed that medical therapy was perceived to be superior to invasive therapy in PBS/IC. Moreover, surgery was correlated with failure to resolve symptoms and several complications in patients with nonulcer PBS/IC. However, a good outcome was recently reported (104, 105) in two studies of patients with classic PBS/IC who underwent reconstructive surgery after failure of various treatments including transurethral resections and intravesical installations. Nevertheless, reconstructive surgery should be reserved only for patients who fail conservative treatment and those with classic PBS/IC; these patients are likely to benefit most.
PBS/IC is chronic multifactorial disease of unclear etiology significantly affecting quality of life and increasing medical costs; average yearly cost per PBS/ICC patient is ϳ$4000 more than that for age-matched controls (106) . Close follow-up of the patients is essential, because prolonged administration of medications may be needed before the alleviation of symptoms. Although lack of numerous RCTs regarding its management is obvious, we propose a treatment algorithm (Figure 2) , based on the best available evidence and giving priority to the less toxic therapies, reserving the more invasive treatments and those with significant adverse effects for the refractory cases.
Evaluation of treatment efficacy in PBS/IC is complicated because of the short duration of trials, the heterogeneity of disease, and the lack of evidence for its natural history. The NIDDK-sponsored trial (58) showed the feasibility of conducting a multicenter RCT in PBS/IC using uniform procedures and outcomes. It is crucial not only to recruit patients following specific inclusion criteria, but also to define objective outcome measures and to continue follow-up for a long period of time after intervention. The latter is essential in a disease with flares and remissions, which would otherwise make it almost impossible to attribute improvement to the intervention and not to disease fluctuation itself. In addition, there should be a consensus regarding objective standardized outcome measures (working or activity hours, physical or sexual activity, etc.); this is particularly significant to ensure that improvement is actually accomplished and that it is not the result of frequent subjective changes observed in patients with chronic disease. Intervention should follow the same protocol to allow a more accurate comparison between trials. Developing evidence-based therapies by conducting appropriately designed RCTs is essential for advancing to safe and effective interventions in patients with this chronic and debilitating disease.
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